Chester County News and Community Website
VALLEY FORGE, PA — AmerisourceBergen Corporation (NYSE: ABC) announced that it priced $500 million aggregate principal amount of its 2.800% Senior Notes due May 15, 2030 (the “Notes”), in an …
Read More
MALVERN, PA — Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the closing of the previously announced public offering, reflective of …
Read More
MALVERN, PA — Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the pricing of an underwritten public offering of 7,692,308 shares …
Read More
WEST CHESTER, PA — QVC, Inc. recently announced its intention to offer $500 million aggregate principal amount of Senior Secured Notes due 2027, subject to market and other conditions.
Read More
MALVERN, PA — TELA Bio, Inc. (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs …
Read More
MALVERN, PA — TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in …
Read More
MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy …
Read More
MALVERN, PA — CubeSmart (NYSE: CUBE) announced that its operating partnership, CubeSmart, L.P. (the “Operating Partnership”), priced an offering of $350.0 million aggregate principal amount of 3.000% senior unsecured notes due 2030 (the …
Read More
PAOLI, PA — Malvern Bancorp, Inc. (NASDAQ: MLVF), the parent company of Malvern Bank, National Association, announced recently the closing of the Company’s previously announced underwritten public offering of 1,190,477 shares of …
Read More
MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (“PhaseBio”), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on cardiopulmonary disorders, recently announced …
Read More